Frontiers in immunology · 2025
Prognostic value of presepsin in sepsis and septic shock: a meta-analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xing Xiaokang, Wang Qianwen, Zhang Yueyue, Zhang Ge
Аннотация
BACKGROUND: Presepsin, an innate immune activation biomarker, shows potential for predicting the prognosis of sepsis, but its predictive accuracy remains unclear. This meta-analysis aims to evaluate its efficiency for predicting the risk of mortality in sepsis and septic shock.
METHODS: Per PRISMA guidelines, four databases were searched until January 2025. Sixteen observational studies with 2,066 patients were included. Pooled sensitivity, specificity, DOR, and AUC were calculated using bivariate random-effects models. The sources of heterogeneity were explored via subgroup analyses and meta-regression. Study quality was assessed with QUADAS-2.
RESULTS: Presepsin showed moderate accuracy for predicting the risk of mortality (pooled AUC 0.80, 95% CI: 0.76-0.83). The pooled sensitivity and specificity were 76% (95% CI: 69-82%) and 70% (95% CI: 59-78%), respectively. Sensitivity was notably higher in patients with septic shock (90%) compared to those with sepsis (75%), whereas specificity was comparatively lower (50% vs. 77%). Substantial heterogeneity stemmed from threshold variability and geographic differences (particularly in Korean cohorts). Prospective studies had higher sensitivity (80%) than retrospective studies (60%). No publication bias was detected.
CONCLUSIONS: Presepsin is a pragmatic biomarker for predicting the risk of mortality, with enhanced sensitivity in septic shock. Presepsin may be integrated into clinical decision-making for early intervention.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42025639268.
METHODS: Per PRISMA guidelines, four databases were searched until January 2025. Sixteen observational studies with 2,066 patients were included. Pooled sensitivity, specificity, DOR, and AUC were calculated using bivariate random-effects models. The sources of heterogeneity were explored via subgroup analyses and meta-regression. Study quality was assessed with QUADAS-2.
RESULTS: Presepsin showed moderate accuracy for predicting the risk of mortality (pooled AUC 0.80, 95% CI: 0.76-0.83). The pooled sensitivity and specificity were 76% (95% CI: 69-82%) and 70% (95% CI: 59-78%), respectively. Sensitivity was notably higher in patients with septic shock (90%) compared to those with sepsis (75%), whereas specificity was comparatively lower (50% vs. 77%). Substantial heterogeneity stemmed from threshold variability and geographic differences (particularly in Korean cohorts). Prospective studies had higher sensitivity (80%) than retrospective studies (60%). No publication bias was detected.
CONCLUSIONS: Presepsin is a pragmatic biomarker for predicting the risk of mortality, with enhanced sensitivity in septic shock. Presepsin may be integrated into clinical decision-making for early intervention.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42025639268.